This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Viking Therapeutics' experimental drug, VK2735, shows promising results in a clinical trial by helping participants maintain weight loss even with monthly dosing. This development could position VK2735 as a strong competitor to Eli Lilly’s Zepbound, which has already gained attention in the weight management market. The drug's success in maintaining weight loss with less frequent dosing could make it more convenient and accessible, potentially attracting a larger patient base and boosting the company's stock performance. This breakthrough highlights the ongoing advancements in GLP-1/GIP drugs and their potential impact on obesity treatment.